59 related articles for article (PubMed ID: 12767092)
1. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.
Favaretto AG; Aversa SM; Paccagnella A; Manzini Vde P; Palmisano V; Oniga F; Stefani M; Rea F; Bortolotti L; Loreggian L; Monfardini S
Cancer; 2003 Jun; 97(11):2791-7. PubMed ID: 12767092
[TBL] [Abstract][Full Text] [Related]
2. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
Kindler HL; Karrison TG; Gandara DR; Lu C; Krug LM; Stevenson JP; Jänne PA; Quinn DI; Koczywas MN; Brahmer JR; Albain KS; Taber DA; Armato SG; Vogelzang NJ; Chen HX; Stadler WM; Vokes EE
J Clin Oncol; 2012 Jul; 30(20):2509-15. PubMed ID: 22665541
[TBL] [Abstract][Full Text] [Related]
3. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
Ceresoli GL; Castagneto B; Zucali PA; Favaretto A; Mencoboni M; Grossi F; Cortinovis D; Del Conte G; Ceribelli A; Bearz A; Salamina S; De Vincenzo F; Cappuzzo F; Marangolo M; Torri V; Santoro A
Br J Cancer; 2008 Jul; 99(1):51-6. PubMed ID: 18542071
[TBL] [Abstract][Full Text] [Related]
4. Ganetespib in Combination with Pemetrexed-Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial.
Fennell DA; Danson S; Woll PJ; Forster M; Talbot D; Child J; Farrelly L; Sharkey A; Busacca S; Ngai Y; Hackshaw A; Wheeler GM
Clin Cancer Res; 2020 Sep; 26(18):4748-4755. PubMed ID: 32669375
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitivity of three patient-derived primary cultures of canine pericardial mesothelioma by single-agent and combination treatment.
Nabeta R; Kanaya A; Elbadawy M; Usui T; Furuya T; Suzuki K; Uchide T
Front Vet Sci; 2023; 10():1267359. PubMed ID: 38026668
[TBL] [Abstract][Full Text] [Related]
6. SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma.
Ashton M; O'Rourke N; Macleod N; Laird B; Stobo J; Kelly C; Alexander L; Franks K; Moore K; Currie S; Valentine R; Chalmers AJ
Clin Transl Radiat Oncol; 2018 Jan; 8():45-49. PubMed ID: 29594241
[TBL] [Abstract][Full Text] [Related]
7. Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma.
de Lima VA; Sørensen JB
Med Oncol; 2015 Feb; 32(2):458. PubMed ID: 25572813
[TBL] [Abstract][Full Text] [Related]
8. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
Vogelzang NJ; Rusthoven JJ; Symanowski J; Denham C; Kaukel E; Ruffie P; Gatzemeier U; Boyer M; Emri S; Manegold C; Niyikiza C; Paoletti P
J Clin Oncol; 2003 Jul; 21(14):2636-44. PubMed ID: 12860938
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
10. Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study.
Mutlu H; Gündüz S; Karaca H; Büyükçelik A; Cihan YB; Erden A; Akca Z; Coşkun HS
Med Oncol; 2014 Aug; 31(8):74. PubMed ID: 24958517
[TBL] [Abstract][Full Text] [Related]
11. Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant Pleural Mesothelioma Treated with Systemic Chemotherapy.
Kotecha R; Tonse R; Rubens M; Appel H; Albrecht F; Kaywin P; Alley EW; Tom MC; Mehta MP
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34063225
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for progression-free and overall survival in malignant pleural mesothelioma.
Guzmán-Casta J; Carrasco-CaraChards S; Guzmán-Huesca J; Sánchez-Ríos CP; Riera-Sala R; Martínez-Herrera JF; Peña-Mirabal ES; Bonilla-Molina D; Alatorre-Alexander JA; Martínez-Barrera LM; Rodríguez-Cid JR
Thorac Cancer; 2021 Apr; 12(7):1014-1022. PubMed ID: 33660947
[TBL] [Abstract][Full Text] [Related]
13. Malignant mesothelioma of the tunica vaginalis testis: a rare case and review of literature.
Drevinskaite M; Patasius A; Kevlicius L; Mickys U; Smailyte G
BMC Cancer; 2020 Feb; 20(1):162. PubMed ID: 32106829
[TBL] [Abstract][Full Text] [Related]
14. Current chemotherapy strategies in malignant pleural mesothelioma.
de Gooijer CJ; Baas P; Burgers JA
Transl Lung Cancer Res; 2018 Oct; 7(5):574-583. PubMed ID: 30450296
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.
Cinausero M; Rihawi K; Sperandi F; Melotti B; Ardizzoni A
J Thorac Dis; 2018 Jan; 10(Suppl 2):S304-S310. PubMed ID: 29507800
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
Kindler HL; Ismaila N; Armato SG; Bueno R; Hesdorffer M; Jahan T; Jones CM; Miettinen M; Pass H; Rimner A; Rusch V; Sterman D; Thomas A; Hassan R
J Clin Oncol; 2018 May; 36(13):1343-1373. PubMed ID: 29346042
[TBL] [Abstract][Full Text] [Related]
17. Novel systemic therapy against malignant pleural mesothelioma.
Mancuso MR; Neal JW
Transl Lung Cancer Res; 2017 Jun; 6(3):295-314. PubMed ID: 28713675
[TBL] [Abstract][Full Text] [Related]
18. Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review.
Hashimoto K; Okuma Y; Hosomi Y; Hishima T
BMC Cancer; 2016 Sep; 16(1):718. PubMed ID: 27599565
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma.
Ak G; Metintas S; Akarsu M; Metintas M
BMC Cancer; 2015 Jul; 15():510. PubMed ID: 26156324
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of piroxicam plus cisplatin-loaded PLGA nanoparticles in inducing apoptosis in mesothelioma cells.
Menale C; Piccolo MT; Favicchia I; Aruta MG; Baldi A; Nicolucci C; Barba V; Mita DG; Crispi S; Diano N
Pharm Res; 2015 Feb; 32(2):362-74. PubMed ID: 25092068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
